Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats

Tween 80 (Polysorbate 80) is a hydrophilic nonionic surfactant commonly used as an ingredient in dosing vehicles for pre-clinicalin vivo studies (e.g., pharmacokinetic studies, etc.). Tween 80 increased apical to basolateral permeability of digoxin in Caco-2 cells suggesting that Tween 80 is anin vitro inhibitor of P-gp. The overall objective of the present study was to investigate whether an inhibition of P-gp by Tween 80 can potentially influencein vivo absorption of P-gp substrates by evaluating the effect of Tween 80 on the disposition of digoxin (a model P-gp substrate with minimum metabolism) after oral administration in rats. Rats were dosed orally with digoxin (0.2 mg/kg) formulated in ethanol (40%, v/v) and saline mixture with and without Tween 80 (1 or 10%, v/v). Digoxin oral AUC increased 30 and 61% when dosed in 1% and 10% Tween 80, respectively, compared to control (P<0.05). To further examine whether the increase in digoxin AUC after oral administration of Tween 80 is due, in part, to a systemic inhibition of digoxin excretion in addition to an inhibition of P-gp in the Gl tract, a separate group of rats received digoxin intravenously (0.2 mg/kg) and Tween 80 (10% v/v) orally. No significant changes in digoxin IV AUC was noted when Tween 80 was administered orally. In conclusion, Tween 80 significantly increased digoxin AUC and Cmax after oral administration, and the increased AUC is likely to be due to an inhibition of P-gp in the gut (i.e., improved absorption). Therefore, Tween 80 is likely to improve systemic exposure of P-gp substrates after oral administration. Comparing AUC after oral administration with and without Tween 80 may be a viable strategy in evaluating whether oral absorption of P-gp substrates is potentially limited by P-gp in the gut.

[1]  Y. Tanigawara Role of P-glycoprotein in drug disposition. , 2000, Therapeutic drug monitoring.

[2]  P. Hinderling,et al.  Pharmacokinetics of Digoxin and Main Metabolites/Derivatives in Healthy Humans , 1991, Therapeutic drug monitoring.

[3]  Leslie Z. Benet,et al.  Effects of Ketoconazole on Digoxin Absorption and Disposition in Rat , 1998, Pharmacology.

[4]  J. Hochman,et al.  In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. , 2001, The Journal of pharmacology and experimental therapeutics.

[5]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.

[6]  S. Chong,et al.  A rapid and sensitive LC/MS/MS assay for quantitative determination of digoxin in rat plasma. , 2003, Journal of pharmaceutical and biomedical analysis.

[7]  M. Polymeropoulos,et al.  Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P‐glycoprotein, in drug‐selected cell lines and patients with drug refractory ALL , 1998, Genes, chromosomes & cancer.

[8]  G R Wilkinson,et al.  Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. , 1999, Circulation.

[9]  R. Borchardt,et al.  Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. , 1997, Journal of pharmaceutical sciences.

[10]  Ronald T Borchardt,et al.  A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. , 2002, Journal of pharmaceutical sciences.

[11]  A. D. Rodrigues,et al.  Drug-drug interactions , 2001, Atkinson's Principles of Clinical Pharmacology.

[12]  Y. Sugiyama,et al.  Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[13]  J. Schellens,et al.  P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. , 1999, Pharmacological research.

[14]  Alexander V. Kabanov,et al.  Effects of Pluronic Block Copolymers on Drug Absorption in Caco-2 Cell Monolayers , 1998, Pharmaceutical Research.

[15]  J. Silverman Multidrug-resistance transporters. , 1999, Pharmaceutical biotechnology.

[16]  L. Benet,et al.  Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[17]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[18]  M. Kool,et al.  The multidrug resistance protein family. , 1999, Biochimica et biophysica acta.

[19]  T. Druley,et al.  From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance , 2001, Cellular and Molecular Life Sciences CMLS.

[20]  E. Iisalo Clinical Pharmacokinetics of Digoxin , 1977, Clinical pharmacokinetics.

[21]  J. Schellens,et al.  The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients , 2001, British Journal of Cancer.

[22]  G. Houin,et al.  Effect of Polyoxyl 35 Castor Oil and Polysorbate 80 on the Intestinal Absorption of Digoxin in vitro , 2000, Arzneimittelforschung.

[23]  M Rowland,et al.  Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. , 2001, The Journal of pharmacology and experimental therapeutics.

[24]  B. Angelin,et al.  Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine , 1990, Clinical pharmacology and therapeutics.